Synthesis and activity of HIV protease inhibitors

被引:18
作者
Garrouste, P
Pawlowski, M
Tonnaire, T
Sicsic, S
Dumy, P
de Rosny, E
Reboud-Ravaux, M
Fulcrand, P
Martinez, J
机构
[1] Univ Montpellier 1, Fac Pharm, UMR 5810, F-34060 Montpellier 2, France
[2] Univ Montpellier 2, Fac Pharm, UMR 5810, F-34060 Montpellier, France
[3] Akad Med, Katedra Chemmii Farmaceut, PL-31065 Krakow, Poland
[4] Fac Pharm Chatenay Malabry, Biocis CNRS, URA 1843, F-92296 Chatenay Malabry, France
[5] Univ Lausanne, BCH Dorigny, Inst Organ Chem, CH-1015 Lausanne, Switzerland
[6] Univ Paris 07, Inst Jacques Monod, F-75251 Paris, France
关键词
HIV; protease; inhibitor; pseudopeptide; cyclic peptide;
D O I
10.1016/S0223-5234(98)80043-3
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We report here the synthesis and activity of HIV protease inhibitors. Ln the first stage hydrophobic compounds incorporating a 'carba' bond surrogate or a beta-homologated residue were synthesized. Secondly, we synthesized cyclic compounds in which we incorporated 2-quinoline carboxylic acid in the P3 position and the amino-hydroxyindane moiety in the P'3. The last part of this work was dedicated to a structure/activity study of a peptide substrate. These modifications allowed us to work up the synthesis of new pseudopeptide bonds: amino-amide and hydroxy-amide, Compounds with activity in the micromolar range were actually a starting point for the synthesis of new protease inhibitors. (C) Elsevier, Paris.
引用
收藏
页码:423 / 436
页数:14
相关论文
共 35 条
[1]   ISOLATION OF A T-LYMPHOTROPIC RETROVIRUS FROM A PATIENT AT RISK FOR ACQUIRED IMMUNE-DEFICIENCY SYNDROME (AIDS) [J].
BARRESINOUSSI, F ;
CHERMANN, JC ;
REY, F ;
NUGEYRE, MT ;
CHAMARET, S ;
GRUEST, J ;
DAUGUET, C ;
AXLERBLIN, C ;
VEZINETBRUN, F ;
ROUZIOUX, C ;
ROZENBAUM, W ;
MONTAGNIER, L .
SCIENCE, 1983, 220 (4599) :868-871
[2]   MOLECULAR MECHANISMS OF IMMUNOSUPPRESSION [J].
BAUMANN, G ;
ZENKE, G ;
WENGER, R ;
HIESTAND, P ;
QUESNIAUX, V ;
ANDERSEN, E ;
SCHREIER, MH .
JOURNAL OF AUTOIMMUNITY, 1992, 5 :67-72
[3]   PROGRESS TOWARDS NEW CONFORMATIONALLY CONSTRAINED HIV-1 PROTEASE INHIBITORS [J].
BENATALAH, Z ;
TRIGUI, N ;
SICSIC, S ;
TONNAIRE, T ;
DEROSNY, E ;
BOGGETTO, N ;
REBOUD, M .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 1995, 30 (11) :891-900
[4]   ANALYSIS OF SUBSITE PREFERENCES OF HIV-1 PROTEINASE USING MA/CA JUNCTION PEPTIDES SUBSTITUTED AT THE P3-P1' POSITIONS [J].
BILLICH, A ;
WINKLER, G .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1991, 290 (01) :186-190
[5]   CYANOHYDRIDOBORATE ANION AS A SELECTIVE REDUCING AGENT [J].
BORCH, RF ;
BERNSTEIN, MD ;
DURST, HD .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1971, 93 (12) :2897-+
[6]   Drug development - Protease inhibitors: A tale of two companies [J].
Cohen, J .
SCIENCE, 1996, 272 (5270) :1882-1883
[7]   HIV-1 PROTEASE SPECIFICITY OF PEPTIDE CLEAVAGE IS SUFFICIENT FOR PROCESSING OF GAG AND POL POLYPROTEINS [J].
DARKE, PL ;
NUTT, RF ;
BRADY, SF ;
GARSKY, VM ;
CICCARONE, TM ;
LEU, CT ;
LUMMA, PK ;
FREIDINGER, RM ;
VEBER, DF ;
SIGAL, IS .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1988, 156 (01) :297-303
[8]   SYNTHESIS AND PHARMACOLOGICAL CHARACTERIZATION INVITRO OF CYCLIC ENKEPHALIN ANALOGS - EFFECT OF CONFORMATIONAL CONSTRAINTS ON OPIATE RECEPTOR SELECTIVITY [J].
DIMAIO, J ;
NGUYEN, TMD ;
LEMIEUX, C ;
SCHILLER, PW .
JOURNAL OF MEDICINAL CHEMISTRY, 1982, 25 (12) :1432-1438
[9]   DESIGN, ACTIVITY, AND 2.8 A CRYSTAL-STRUCTURE OF A C2 SYMMETRICAL INHIBITOR COMPLEXED TO HIV-1 PROTEASE [J].
ERICKSON, J ;
NEIDHART, DJ ;
VANDRIE, J ;
KEMPF, DJ ;
WANG, XC ;
NORBECK, DW ;
PLATTNER, JJ ;
RITTENHOUSE, JW ;
TURON, M ;
WIDEBURG, N ;
KOHLBRENNER, WE ;
SIMMER, R ;
HELFRICH, R ;
PAUL, DA ;
KNIGGE, M .
SCIENCE, 1990, 249 (4968) :527-533
[10]  
FEHRENTZ JA, 1983, SYNTHESIS-STUTTGART, P676